Study of Tirzepatide for Recovery and Alcohol Use Management
Condition: Alcohol Use Disorder (AUD) · Sponsor: Brigham and Women's Hospital
About this study
This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.
This description comes directly from the study's public registry record.
Talk to the study team
Joji Suzuki, MD · 617-732-5752 · jsuzuki2@bwh.harvard.edu
Laura M Holsen, Ph.D. · 617-525-8772 · lholsen@bwh.harvard.edu
Always discuss trial participation with your own doctor first.
Locations (2)
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Active Not Recruiting |
| Brigham and Women's Faulkner Hospital | Jamaica Plain, Massachusetts, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06727331